The Canadian Immunocompromised Advocacy Network (CIAN) – Advocating for immunocompromised people across Canada

by admin | Apr 19, 2024 | Article

February 14, 2024 – “In the spring of 2022, even as COVID-19 restrictions were being lifted across the country (and the world), there was still a great deal of concern from immunocompromised patients about how they navigate the ‘post-pandemic world’. In response...

Using CyTOF to dissect the interplay between Type I interferon and autoantibody production in Systemic Lupus Erythematosus

by admin | Apr 19, 2024 | Article

Dr. Joan Wither Senior Scientist, Krembil Research Institute Professor of Medicine and Immunology, University of Toronto Director of STAT (Urgent Assessment) Rheumatology Clinic, Toronto Western Hospital Director of Early Autoimmune Rheumatic Disease Clinic, Toronto...

Now Enrolling People with Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) For A Research Study.

by admin | Apr 19, 2024 | Article

Now Enrolling People with Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) For A Research Study Study Title:Phase 2 ALXN1210-NEPH-202 Study (clinicaltrials.gov NCT04564339) Study Sponsor:Alexion, Astra Zeneca Rare Disease Purpose of Study:The purpose of...

COVID-19 VACCINE ROLLOUT

by admin | Apr 19, 2024 | Article

As provincial governments begin their rollout plans for the COVID-19 vaccine we encourage you to speak with your healthcare team or...

AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis

by admin | Apr 19, 2024 | Article

https://www.lupuscanada.org/wp-content/uploads/AZD1222_PhIII-US-HLR_RNS.pdf

Dr. Samir Gupta explains how the four COVID-19 vaccines now approved in Canada work and why efficacy rates aren’t the most important number to look at.

by admin | Apr 19, 2024 | Article

https://www.cbc.ca/player/play/1880969283645